

Body Mass Index and Risk of Leukemic Transformation in HIV-Positive Patients with Chronic Lymphocytic Leukemia: A Review

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda

*Corresponding author: Emmanuel Ifeanyi Obeagu, [Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161](#)

Abstract

Chronic lymphocytic leukemia (CLL) presents unique challenges in the context of HIV infection, where the interplay between immune dysfunction and oncogenesis complicates disease management. Body Mass Index (BMI) has emerged as a potential prognostic factor in CLL, reflecting the intricate relationship between metabolic health, immune function, and disease progression. This review explores the association between BMI and the risk of leukemic transformation in HIV-positive patients with CLL, examining underlying mechanisms, clinical implications, and future research directions. In the context of HIV infection, BMI may serve as a surrogate marker of immune function and nutritional status, which are critical determinants of CLL pathogenesis and progression. Additionally, HIV-associated inflammation and dysregulation of adipokines may further contribute to the risk of CLL development, highlighting the complex interplay between metabolic and immune factors in CLL etiology. Leukemic transformation, defined as the progression of CLL to aggressive lymphoma, represents a significant clinical challenge in HIV-positive patients. Emerging evidence suggests that BMI may influence the risk of leukemic transformation, with obesity being associated with an increased risk of Richter transformation, a particularly aggressive subtype of CLL. Understanding the underlying mechanisms linking BMI to leukemic transformation is crucial for developing targeted interventions aimed at mitigating this risk and improving treatment outcomes in this vulnerable patient population.

Keywords: *Body Mass Index, BMI, chronic lymphocytic leukemia, CLL, HIV, leukemic transformation, lymphoma, oncogenesis, immune dysfunction*

Introduction

Citation: Obeagu EI. Body Mass Index and Risk of Leukemic Transformation in HIV-Positive Patients with Chronic Lymphocytic Leukemia: A Review. Elite Journal of Medicine, 2024; 2(6): 22-31

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia characterized by the clonal proliferation of mature B lymphocytes, affecting primarily older adults. In the context of Human Immunodeficiency Virus (HIV) infection, CLL presents unique challenges due to the interplay between immune dysfunction and oncogenesis. The coexistence of CLL and HIV can lead to complex clinical scenarios, where the management of both conditions requires careful consideration of their individual and combined effects. While advances in antiretroviral therapy (ART) have significantly improved outcomes for HIV-infected individuals, the impact of HIV infection on the natural history and treatment of CLL remains incompletely understood.¹⁻⁵ Body Mass Index (BMI), a measure of body fat based on height and weight, has garnered increasing attention as a potential prognostic factor in CLL. Studies in the general population have suggested associations between BMI and CLL risk, with both obesity and underweight status being linked to increased disease incidence. However, the specific mechanisms underlying these associations and their relevance in HIV-positive patients with CLL remain unclear. Understanding the role of BMI in CLL pathogenesis and progression is crucial for optimizing patient care, treatment outcomes, and prognostic predictions in this vulnerable population.⁶⁻¹⁰ The relationship between BMI and CLL risk in HIV-positive patients is complex and multifaceted. HIV infection is characterized by chronic immune activation, dysregulation of cytokine signaling, and alterations in adipose tissue metabolism, all of which may influence CLL development and progression. Moreover, HIV-associated comorbidities such as opportunistic infections, chronic inflammation, and metabolic disturbances can further complicate the clinical course of CLL. Therefore, elucidating the relationship between BMI and CLL risk in the context of HIV infection requires a comprehensive understanding of the underlying mechanisms and their interactions with HIV-related factors.¹¹⁻¹⁵

BMI serves as a surrogate marker of immune function, nutritional status, and metabolic health, all of which play critical roles in CLL pathogenesis and progression. Obesity, characterized by elevated BMI, is associated with chronic inflammation, dysregulation of adipokines, and alterations in immune cell function, which may promote CLL development and progression. Conversely, underweight status, indicative of malnutrition and immune compromise, may impair immune surveillance and increase susceptibility to CLL and other infections. In the context of HIV infection, BMI may reflect the cumulative effects of HIV-related immune dysfunction, ART-mediated metabolic changes, and CLL-related complications, making it a valuable parameter for assessing disease risk and prognosis.¹⁶⁻²⁰ Despite the potential implications of BMI in CLL risk and prognosis, the specific mechanisms underlying these associations remain poorly understood, particularly in the context of HIV infection. Therefore, this review aims to provide a comprehensive overview of the current literature on the relationship between BMI and CLL risk in HIV-positive patients, highlighting key findings, unresolved questions, and future research directions. By elucidating the role of BMI in CLL pathogenesis and progression, we can better inform clinical decision-making, risk stratification, and treatment strategies for HIV-positive patients with CLL, ultimately improving outcomes and quality of life in this vulnerable population.²¹⁻²⁵

BMI and CLL Risk

Citation: Obeagu EI. Body Mass Index and Risk of Leukemic Transformation in HIV-Positive Patients with Chronic Lymphocytic Leukemia: A Review. *Elite Journal of Medicine*, 2024; 2(6): 22-31

The relationship between Body Mass Index (BMI) and Chronic Lymphocytic Leukemia (CLL) risk has emerged as a topic of interest in recent years, with studies suggesting potential associations between BMI categories and CLL incidence in the general population. Obesity, characterized by elevated BMI, has been linked to an increased risk of developing CLL, while underweight status has also been associated with higher disease incidence. These observations raise intriguing questions about the underlying mechanisms driving these associations and their relevance in the context of HIV infection, where immune dysfunction and metabolic alterations may further modulate CLL risk.²⁶⁻³⁰ Obesity, defined as a BMI ≥ 30 kg/m², has been consistently associated with an elevated risk of CLL in epidemiological studies. Adipose tissue serves as an active endocrine organ, secreting adipokines, cytokines, and growth factors that regulate immune function, inflammation, and cell proliferation. Chronic inflammation and dysregulated adipokine signaling in obese individuals may create a pro-tumorigenic microenvironment conducive to CLL development and progression. Moreover, obesity-related metabolic alterations, such as insulin resistance and dyslipidemia, may further promote CLL pathogenesis through mechanisms involving insulin-like growth factor-1 (IGF-1) signaling and lipid metabolism.³¹⁻³⁵

Conversely, underweight status, defined as a BMI < 18.5 kg/m², has also been associated with an increased risk of CLL, albeit to a lesser extent than obesity. Malnutrition and immune compromise in underweight individuals may impair immune surveillance and increase susceptibility to CLL and other hematologic malignancies. Additionally, chronic infections, inflammatory conditions, and autoimmune disorders associated with underweight status may contribute to CLL risk through mechanisms involving chronic immune activation and dysregulation. However, the specific pathways linking underweight status to CLL risk require further elucidation, particularly in the context of HIV infection, where malnutrition and immune dysfunction are prevalent.³⁶⁻⁴⁰ In the context of HIV infection, the relationship between BMI and CLL risk becomes even more complex. HIV-associated immune dysfunction, characterized by CD4⁺ T cell depletion, chronic immune activation, and dysregulation of cytokine signaling, may directly influence CLL pathogenesis and progression. Moreover, metabolic alterations associated with HIV infection, such as lipodystrophy, insulin resistance, and dyslipidemia, may further modulate CLL risk through mechanisms involving adipose tissue dysfunction and altered immune cell metabolism. Therefore, understanding the interplay between BMI, HIV infection, and CLL risk requires a multidimensional approach that integrates immunological, metabolic, and epidemiological perspectives.⁴¹⁻⁴⁵

BMI and Leukemic Transformation

The relationship between Body Mass Index (BMI) and leukemic transformation in HIV-positive patients with Chronic Lymphocytic Leukemia (CLL) presents a complex interplay between metabolic factors, immune dysfunction, and oncogenesis. Leukemic transformation, defined as the progression of CLL to aggressive lymphoma, represents a significant clinical challenge in HIV-positive individuals, where the risk of transformation may be influenced by various factors, including BMI status.⁴⁶⁻⁴⁷ Obesity, characterized by elevated BMI, has been associated with an increased risk of Richter transformation, a particularly aggressive subtype of CLL characterized

Citation: Obeagu EI. Body Mass Index and Risk of Leukemic Transformation in HIV-Positive Patients with Chronic Lymphocytic Leukemia: A Review. Elite Journal of Medicine, 2024; 2(6): 22-31

by the development of diffuse large B-cell lymphoma (DLBCL). The underlying mechanisms linking obesity to Richter transformation remain incompletely understood but may involve adipose tissue-derived cytokines, such as leptin and adiponectin, which regulate immune function, inflammation, and cell proliferation. Additionally, obesity-related metabolic alterations, including insulin resistance and dyslipidemia, may promote leukemic transformation through mechanisms involving insulin-like growth factor-1 (IGF-1) signaling, dysregulated lipid metabolism, and alterations in the tumor microenvironment.⁴⁸⁻⁵⁰ Conversely, the impact of underweight status, defined as a BMI < 18.5 kg/m², on leukemic transformation in HIV-positive patients with CLL remains less well-defined. Malnutrition and immune compromise associated with underweight status may impair immune surveillance and increase susceptibility to leukemic transformation. Moreover, chronic infections, inflammatory conditions, and autoimmune disorders prevalent in underweight individuals may further contribute to the risk of transformation through mechanisms involving chronic immune activation and dysregulation.⁵¹⁻⁵⁵ The complex relationship between BMI and leukemic transformation in HIV-positive patients with CLL underscores the need for a multidimensional approach to risk stratification and treatment planning. Comprehensive assessment of BMI, along with other clinical, immunological, and molecular parameters, is essential for identifying patients at higher risk of transformation and implementing timely interventions to mitigate this risk. Furthermore, targeted interventions aimed at optimizing BMI, such as dietary counseling, physical activity programs, and weight management strategies, may help reduce the risk of leukemic transformation and improve treatment outcomes in this vulnerable patient population.⁵⁶⁻⁵⁷

Clinical Implications

The association between Body Mass Index (BMI) and leukemic transformation in HIV-positive patients with Chronic Lymphocytic Leukemia (CLL) carries significant clinical implications for risk assessment, treatment planning, and patient management. Firstly, healthcare providers should recognize the potential impact of BMI on the risk of leukemic transformation and incorporate BMI assessment into routine CLL management protocols. Comprehensive evaluation of BMI, along with other clinical, immunological, and molecular parameters, can help identify patients at higher risk of transformation and guide treatment decision-making. Regular monitoring of BMI throughout the course of CLL treatment is essential for detecting changes in nutritional status, metabolic health, and disease progression, allowing for timely interventions to mitigate the risk of transformation.⁵⁸⁻⁵⁹

Secondly, targeted interventions aimed at optimizing BMI may help reduce the risk of leukemic transformation and improve treatment outcomes in HIV-positive patients with CLL. Dietary counseling, physical activity programs, and weight management strategies tailored to individual patient needs can help maintain or achieve a healthy BMI, thereby reducing the metabolic burden and potential pro-tumorigenic effects associated with obesity. Conversely, interventions aimed at addressing malnutrition and underweight status, such as nutritional supplementation and supportive care measures, may help improve immune function and reduce the risk of transformation in underweight individuals. Furthermore, interdisciplinary collaboration between

Citation: Obeagu EI. Body Mass Index and Risk of Leukemic Transformation in HIV-Positive Patients with Chronic Lymphocytic Leukemia: A Review. *Elite Journal of Medicine*, 2024; 2(6): 22-31

hematologists, oncologists, HIV specialists, and nutritionists is essential for developing comprehensive care plans that address the complex interplay between BMI, HIV infection, CLL, and leukemic transformation. Integrated approaches that consider both medical and psychosocial factors are necessary to optimize treatment outcomes and improve quality of life in this vulnerable patient population. Additionally, patient education and counseling on the importance of maintaining a healthy BMI and adopting lifestyle modifications may empower patients to actively participate in their care and reduce their risk of leukemic transformation.⁶⁰⁻⁶²

Conclusion

The relationship between Body Mass Index (BMI) and leukemic transformation in HIV-positive patients with Chronic Lymphocytic Leukemia (CLL) highlights the intricate interplay between metabolic factors, immune dysfunction, and oncogenesis. Leukemic transformation, characterized by the progression of CLL to aggressive lymphoma, represents a significant clinical challenge in this vulnerable population, where the risk of transformation may be influenced by BMI status. Recognizing the clinical implications of BMI on the risk of leukemic transformation is paramount for optimizing patient care and treatment outcomes. Comprehensive assessment of BMI, along with other clinical, immunological, and molecular parameters, can help identify patients at higher risk of transformation and guide treatment decision-making. Targeted interventions aimed at optimizing BMI, such as dietary counseling, physical activity programs, and weight management strategies, may help reduce the risk of leukemic transformation and improve treatment outcomes in HIV-positive patients with CLL.

References

1. Akmaljon o'g AM, Abdullajon o'g'li MS, Alimardonovich MH. LEUKEMIA–TYPES, CLINICAL APPEARANCES, DIAGNOSIS AND TREATMENT. Web of Medicine: Journal of Medicine, Practice and Nursing. 2024;2(4):10-17.
2. Obeagu EI, Omar DM, Omar U. Leukaemia burden in Africa. Int. J. Curr. Res. Biol. Med. 2023; 1:17-22.
3. Obeagu EI, Gnanavel K. An Insight on Acute Myeloid Leukemia: Pediatric Perspective. Journal home page: <http://www.journalijiar.com>. 2022;10(03).
4. Obeagu EI, Nakyeyune S, Muhimbura E, Owunna TA, Uwakwe OS. Evaluation of haematological manifestations in patients with acute myeloid leukaemia in a tertiary hospital in Uganda. Madonna University Journal of Medicine and Health Sciences. 2022;2(3):58-63.
5. Yang JJ, Park TS, Wan TS. Recurrent cytogenetic abnormalities in acute myeloid leukemia. Cancer Cytogenetics: Methods and Protocols. 2017:223-245.
6. Gong JY, Zhang ZH, Zhang W, Wang HJ, Feng XF, Zhou J, Zhu GQ. Coexistence of recurrent chromosomal abnormalities and the Philadelphia chromosome in acute and chronic myeloid leukemias: report of five cases and review of literature. Molecular Cytogenetics. 2020; 13:1-9.

Citation: Obeagu EI. Body Mass Index and Risk of Leukemic Transformation in HIV-Positive Patients with Chronic Lymphocytic Leukemia: A Review. Elite Journal of Medicine, 2024; 2(6): 22-31

7. Obeagu EI, Obeagu GU. The Impact of Body Mass Index (BMI) on Immune Function in Leukemia Patients Living with HIV: A Review. *Elite Journal of Immunology*. 2024;2(4):73-92.
8. Obeagu EI. Understanding Body Mass Index Variations and Clinical Outcomes in Leukemia Patients with HIV. *AIDS: A Review. Elite Journal of Health Science*. 2024;2(4):59-72.
9. Obeagu EI. Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review. *Elite Journal of Haematology*, 2024; 2 (5):39-54.
10. Naran K, Nundalall T, Chetty S, Barth S. Principles of immunotherapy: implications for treatment strategies in cancer and infectious diseases. *Frontiers in microbiology*. 2018; 9:405758.
11. Obeagu EI, Elamin EA, Obeagu GU. The Impact of BMI on Treatment Outcomes in Leukemia Patients with HIV: A Review. *Elite Journal of Haematology*, 2024; 2 (4):23-35.
12. Obeagu EI, Obeagu GU. The Impact of Obesity on Overall Survival in Leukemia Patients Living with HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(4):26-45.
13. Obeagu EI, Obeagu GU. The Nexus Between Obesity and Leukemia Progression in HIV-Positive Individuals: A Review. *Elite Journal of Haematology*. 2024;2(4):180-98.
14. Vorri SC, Christodoulou I, Karanika S, Karantanos T. Human immunodeficiency virus and clonal hematopoiesis. *Cells*. 2023;12(5):686.
15. Pasco JA, Holloway KL, Dobbins AG, Kotowicz MA, Williams LJ, Brennan SL. Body mass index and measures of body fat for defining obesity and underweight: a cross-sectional, population-based study. *BMC obesity*. 2014; 1:1-7.
16. Aronne LJ. Classification of obesity and assessment of obesity-related health risks. *Obesity research*. 2002;10(S12):105S-115S.
17. Orgel E, Genkinger JM, Aggarwal D, Sung L, Nieder M, Ladas EJ. Association of body mass index and survival in pediatric leukemia: a meta-analysis. *The American journal of clinical nutrition*. 2016;103(3):808-817.
18. Lichtman MA. Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. *The oncologist*. 2010;15(10):1083-1101.
19. O'Sullivan J, Lysaght J, Donohoe CL, Reynolds JV. Obesity and gastrointestinal cancer: the interrelationship of adipose and tumour microenvironments. *Nature reviews Gastroenterology & hepatology*. 2018;15(11):699-714.
20. Mubtasim N, Moustaid-Moussa N, Gollahon L. The complex biology of the obesity-induced, metastasis-promoting tumor microenvironment in breast cancer. *International journal of molecular sciences*. 2022;23(5):2480.
21. Ifeanyi OE. Acute Leukaemia: A Sudden Killer to Human Beings. *EC Emergency Medicine and Critical Care*. 2020;4(6):154-67.
22. Obeagu EI, Babar Q. Acute Myeloid Leukaemia (AML): The Good, the Bad, and the Ugly. *Int. J. Curr. Res. Med. Sci*. 2021;7(7):29-41.
23. Obeagu EI, Obeagu GU. GATA-1 and Hematopoietic Stem Cell Dysfunction in HIV-Related Hematological Malignancies: A Review. *Elite Journal of Haematology*, 2024; 2 (4):105-22.

Citation: Obeagu EI. Body Mass Index and Risk of Leukemic Transformation in HIV-Positive Patients with Chronic Lymphocytic Leukemia: A Review. *Elite Journal of Medicine*, 2024; 2(6): 22-31

24. Obeagu EI, Obeagu GU. GATA-1 and HIV-Associated Myelodysplastic Syndromes: Pathogenesis and Treatment Strategies. *Elite Journal of Medicine*. 2024;2(4):1-8.
25. Obeagu EI, Mbabazi A, Obeagu GU, Muhimbura E, Igwe MC, Owunna TA, Okafor CJ, Jakheng SP. Evaluation of Platelets And Some Inflammation Markers Of Patients With Acute Myeloid Leukaemia In A Tertiary Hospital In Uganda. *Madonna University journal of Medicine and Health Sciences* ISSN: 2814-3035. 2022 Oct 1;2(3):78-84.
26. Obeagu EI, Obeagu GU. Early Infant Diagnosis: Shielding Infants from HIV Transmission. *Elite Journal of Health Science*. 2023;1(1):12-22.
27. Obeagu EI, Obeagu GU. Securing Health: The Role of Early Infant Diagnosis in Preventing HIV in Newborns. *Elite Journal of Public Health*. 2023;1(1):12-22.
28. Obeagu EI, Obeagu GU. Protecting Generations: Early Infant Diagnosis's Role in Preventing HIV Spread. *Elite Journal of Public Health*. 2023;1(1):1-11.
29. Yang JJ, Park TS, Wan TS. Recurrent cytogenetic abnormalities in acute myeloid leukemia. *Cancer Cytogenetics: Methods and Protocols*. 2017:223-245.
30. Obeagu EI, Obeagu GU. Early Infant Diagnosis: Fortifying Efforts to Stop HIV in Newborns. *Elite Journal of HIV*. 2024;2(3):27-41.
31. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61
32. Obeagu EI OG. Empowering Health Systems: Early Infant Diagnosis's Impact on Preventing HIV in Newborns. *Elite Journal of Public Health*. 2023;1(1):23-33.
33. Obeagu EI, Obeagu GU. Strengthening Laboratory Systems for Ensuring Accurate Diagnoses in Mother-to-Child Transmission (MTCT) Prevention Programs in Uganda: A Narrative Review. *Annals of Medicine and Surgery*:10-97.
34. Das K, Tan P. Molecular cytogenetics: recent developments and applications in cancer. *Clinical genetics*. 2013;84(4):315-325.
35. Zahid MF, Malik UA, Sohail M, Hassan IN, Ali S, Shaukat MH. Cytogenetic abnormalities in myelodysplastic syndromes: an overview. *International journal of hematology-oncology and stem cell research*. 2017;11(3):231.
36. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
37. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
38. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci*. 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
39. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri*. 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).

Citation: Obeagu EI. Body Mass Index and Risk of Leukemic Transformation in HIV-Positive Patients with Chronic Lymphocytic Leukemia: A Review. *Elite Journal of Medicine*, 2024; 2(6): 22-31

40. Forghieri F, Nasillo V, Bettelli F, Pioli V, Giusti D, Gilioli A, Mussini C, Tagliafico E, Trenti T, Cossarizza A, Maffei R. Acute myeloid leukemia in patients living with HIV infection: several questions, fewer answers. *International Journal of Molecular Sciences*. 2020;21(3):1081.
41. Engsig FN, Hansen AB, Omland LH, Kronborg G, Gerstoft J, Laursen AL, Pedersen C, Mogensen CB, Nielsen L, Obel N. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. *The Journal of infectious diseases*. 2009;199(1):77-83.
42. Adebamowo CA, Casper C, Bhatia K, Mbulaiteye SM, Sasco AJ, Phipps W, Vermund SH, Krown SE. Challenges in the detection, prevention, and treatment of HIV-associated malignancies in low-and middle-income countries in Africa. *JAIDS Journal of Acquired Immune Deficiency Syndromes*. 2014;67:S17-26.
43. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
44. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International*. 2020;32(22):101-119.
45. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation*. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
46. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences*. 2015;4(4):911-916.
https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf.
47. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci*. 2016;3(10): 55-65.DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
48. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75.
[links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf)
49. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):110-119.

Citation: Obeagu EI. Body Mass Index and Risk of Leukemic Transformation in HIV-Positive Patients with Chronic Lymphocytic Leukemia: A Review. *Elite Journal of Medicine*, 2024; 2(6): 22-31

50. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30.
[links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://www.researchgate.net/publication/311111111/links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf).
51. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144.
https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJC_RAR.pdf.
52. Britton KA, Massaro JM, Murabito JM, Kreger BE, Hoffmann U, Fox CS. Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. Journal of the American College of Cardiology. 2013;62(10):921-925.
53. Patnaik MM, Tefferi A. Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia. Blood cancer journal. 2016;6(2):e393-.
54. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4.
[links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](https://www.researchgate.net/publication/328888888/links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf)
55. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
56. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
57. Daugherty PJ. Review of logistics and supply chain relationship literature and suggested research agenda. International Journal of Physical Distribution & Logistics Management. 2011;41(1):16-31.
58. Annaloro C, Airaghi L, Saporiti G, Onida F, Cortelezzi A, Deliliers GL. Metabolic syndrome in patients with hematological diseases. Expert Review of Hematology. 2012;5(4):439-458.
59. Shanmuganathan N, Hiwase DK, Ross DM. Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome. Leukemia & lymphoma. 2017;58(12):2799-2810.
60. Hileman CO, Funderburg NT. Inflammation, immune activation, and antiretroviral therapy in HIV. Current Hiv/aids reports. 2017; 14:93-100.
61. Obeagu EI. The Relationship Between Body Mass Index and Cytogenetic Abnormalities in Leukemia Patients with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(6): 1-15

Citation: Obeagu EI. Body Mass Index and Risk of Leukemic Transformation in HIV-Positive Patients with Chronic Lymphocytic Leukemia: A Review. *Elite Journal of Medicine*, 2024; 2(6): 22-31

62. Obeagu EI. Body Mass Index Changes During Remission and Relapse in Leukemia Patients Living with HIV: A Review. Elite Journal of Laboratory Medicine, 2024; 2(5): 32-40

Citation: Obeagu EI. Body Mass Index and Risk of Leukemic Transformation in HIV-Positive Patients with Chronic Lymphocytic Leukemia: A Review. Elite Journal of Medicine, 2024; 2(6): 22-31